am-ee-OH-da-rone 
Unlabeled Use:
Absorption: Slowly and variably absorbed from the GI tract (35–65%). IV administration results in complete bioavailability.
Distribution: Distributed to and accumulates slowly in body tissues. Reaches high levels in fat, muscle, liver, lungs, and spleen. Crosses the placenta and enters breast milk.
Protein Binding: 96% bound to plasma proteins.
Metabolism/Excretion: Metabolized by the liver, excreted into bile. Minimal renal excretion. One metabolite has antiarrhythmic activity.
Half-life: 13–107 days.
(suppression of ventricular arrhythmias)
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| PO | 2–3 days (up to 2–3 mo) | 3–7 hr | wk–mos |
| IV | 2 hr | 3–7 hr | unknown |
Contraindicated in:
Use Cautiously in:
CV: bradycardia, hypotension, QT interval prolongation, HF, WORSENING OF ARRHYTHMIAS.
Derm: photosensitivity, blue discoloration, TOXIC EPIDERMAL NECROLYSIS (RARE).
EENT: corneal microdeposits, abnormal sense of smell, dry eyes, optic neuritis, optic neuropathy, photophobia.
Endo: hypothyroidism, hyperthyroidism.
GI: anorexia, constipation, nausea, vomiting, ↑ liver enzymes, abdominal pain, abnormal sense of taste.
GU: ↓ libido, epididymitis.
Neuro: ataxia, dizziness, fatigue, involuntary movement, malaise, paresthesia, peripheral neuropathy, poor coordination, tremor, confusional states, disorientation, hallucinations, headache, insomnia.
Resp: ACUTE RESPIRATORY DISTRESS SYNDROME, PULMONARY FIBROSIS.
Drug-Drug:
Drug-Natural Products:
Drug-Food:
Ventricular Arrhythmias
(Generic available)
IV Administration:
NDC Code*